HMX2 and acute myeloid leukemia: Here, extended expression profiling analyses for HMX2 revealed aberrant gene activity in 5/251 (2.0%) AML patients with normal karyotype (GSE15434), 5/286 (1.7%) with normal or abnormal karyotype (GSE61804), and in 3/96 (3.1%) AML patients with myelodysplastic syndrome (MDS)-related changes and those whose disease was classified as not otherwise specified (GSE21261), indicating rather low incidence overall (S1A–S1C Fig).